国家医保局就《参照药预沟通办法（试行）》公开征求意见

Core Viewpoint - The National Healthcare Security Administration (NHSA) has drafted a consultation document for the adjustment of the medical insurance drug catalog, aiming to stabilize expectations among pharmaceutical companies [1] Group 1: Consultation Process - The consultation for reference drug communication will be organized by the NHSA's Drug Price and Procurement Guidance Center [1] - Pharmaceutical companies can voluntarily apply for reference drug communication, and the center will verify the authenticity and completeness of the submitted materials before providing feedback on whether the application is accepted [1] - The NHSA will periodically organize expert evaluations, with the list of accepted drugs and companies being publicly announced by the end of the month prior to the evaluation [1] Group 2: Expert Involvement - The evaluation experts will come from various fields, including clinical medicine, pharmacy, pharmacoeconomics, and healthcare management [1] - There will be no face-to-face communication between experts and companies during the pre-communication process; experts will primarily rely on the materials provided by the companies for their evaluations [1] - Companies can contest the evaluation results within a specified timeframe by providing additional evidence, which may lead to a second evaluation if deemed necessary [1]